

Daniel B Schmolze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5720554/publications.pdf>

Version: 2024-02-01

46
papers

1,143
citations

394421

19
h-index

414414

32
g-index

48
all docs

48
docs citations

48
times ranked

2091
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of breast pathologies using nonlinear microscopy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15304-15309.	7.1	169
2	Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nature Immunology, 2019, 20, 1220-1230.	14.5	117
3	Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. Clinical Cancer Research, 2020, 26, 657-668.	7.0	70
4	Raman Spectroscopy for Rapid Evaluation of Surgical Margins during Breast Cancer Lumpectomy. Scientific Reports, 2019, 9, 14639.	3.3	61
5	EMDomics: a robust and powerful method for the identification of genes differentially expressed between heterogeneous classes. Bioinformatics, 2016, 32, 533-541.	4.1	60
6	Characterization and Analysis of the Composition and Dynamics of the Mammalian Riboproteome. Cell Reports, 2013, 4, 1276-1287.	6.4	50
7	A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. Oncologist, 2021, 26, 99-e217.	3.7	49
8	Advances in Microscopy Techniques. Archives of Pathology and Laboratory Medicine, 2011, 135, 255-263.	2.5	41
9	Direct comparison between confocal and multiphoton microscopy for rapid histopathological evaluation of unfixed human breast tissue. Journal of Biomedical Optics, 2016, 21, 126021.	2.6	34
10	Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clinical Cancer Research, 2019, 25, 544-551.	7.0	34
11	Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. European Journal of Cancer, 2021, 154, 11-20.	2.8	34
12	Crowdsourcing scoring of immunohistochemistry images: Evaluating Performance of the Crowd and an Automated Computational Method. Scientific Reports, 2017, 7, 43286.	3.3	31
13	Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PLoS ONE, 2019, 14, e0224726.	2.5	29
14	Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2. Scientific Reports, 2018, 8, 15154.	3.3	28
15	Towards integration of ⁶⁴ Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2+ breast cancer. Scientific Reports, 2020, 10, 20518.	3.3	28
16	Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. Oncologist, 2021, 26, e382-e393.	3.7	27
17	Accuracy of gross intraoperative margin assessment for breast cancer: experience since the SSO-ASTRO margin consensus guidelines. Scientific Reports, 2020, 10, 17344.	3.3	26
18	Raman spectroscopy and artificial intelligence to predict the Bayesian probability of breast cancer. Scientific Reports, 2021, 11, 6482.	3.3	23

#	ARTICLE	IF	CITATIONS
19	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 119.	5.0	21
20	Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. <i>Oncolimmunology</i> , 2017, 6, e1363138.	4.6	20
21	Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis. <i>PLoS ONE</i> , 2020, 15, e0229955.	2.5	20
22	Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes. <i>BMC Cancer</i> , 2019, 19, 881.	2.6	19
23	Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. <i>Clinical Cancer Research</i> , 2018, 24, 395-406.	7.0	18
24	Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-“positive breast cancer. <i>JCI Insight</i> , 2022, 7, .	5.0	17
25	Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer. , 2021, 9, e002084.		16
26	Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome. <i>Npj Breast Cancer</i> , 2021, 7, 84.	5.2	16
27	Physics approaches to the spatial distribution of immune cells in tumors. <i>Reports on Progress in Physics</i> , 2021, 84, 022601.	20.1	10
28	Hyperthermic Intraperitoneal Chemotherapy-“Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100239.	3.0	10
29	[Regular Paper] MVPNets: Multi-viewing Path Deep Learning Neural Networks for Magnification Invariant Diagnosis in Breast Cancer. , 2018, , .		9
30	MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 603-612.e7.	0.7	9
31	Value of Additional Level Sections in the Evaluation of Lymph Nodes for Endometrial Carcinoma Staging. <i>American Journal of Clinical Pathology</i> , 2013, 140, 516-518.	0.7	7
32	Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 2795.	3.7	7
33	Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases. <i>European Journal of Radiology</i> , 2021, 144, 109948.	2.6	6
34	Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. <i>Cancers</i> , 2022, 14, 3159.	3.7	5
35	Using Point of Care Glucose Meters in the Critically Ill. <i>Point of Care</i> , 2016, 15, 137-143.	0.4	4
36	A 63-Year-Old Man With Rapidly Progressive Dementia. <i>Clinical Infectious Diseases</i> , 2016, 63, 138-139.	5.8	4

#	ARTICLE	IF	CITATIONS
37	Quantitative Impact of the 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Practice Guideline Update on Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: A Systematic Analysis. Archives of Pathology and Laboratory Medicine, 2021, 145, 887-890.	2.5	4
38	Occupancy and Fractal Dimension Analyses of the Spatial Distribution of Cytotoxic (CD8+) T Cells Infiltrating the Tumor Microenvironment in Triple Negative Breast Cancer. Biophysical Reviews and Letters, 2020, 15, 83-98.	0.8	3
39	Lejomyoadenomatoid Tumor of Epididymis: A Variant of Adenomatoid Tumor. Annals of Clinical and Laboratory Science, 2020, 50, 813-817.	0.2	2
40	An Automatable Method for Determining Adequacy of Thyroid Fine-Needle Aspiration Samples. Archives of Pathology and Laboratory Medicine, 2019, 143, 1084-1088.	2.5	1
41	Stressed out and fed up: The effect of stress on maternal feeding behaviors and the moderating role of executive function. Appetite, 2022, 168, 105762.	3.7	1
42	Molecular Imaging of HER2 in Patient Tissues with Touch Prep-Quantitative Single Molecule Localization Microscopy. Methods in Molecular Biology, 2022, 2394, 231-248.	0.9	1
43	Distribution of Cholesterol and HER2 in Patient Breast Cancer Cells using Quantitative Single Molecule Localization Microscopy. Biophysical Journal, 2019, 116, 440a.	0.5	0
44	Clinical vs genomic risks in breast cancer in 2019: Breast pathologist's appellate review of the controversial results from TAILORx trial. Breast Journal, 2020, 26, 1447-1448.	1.0	0
45	Abstract 2172: Earth mover's distance for the identification of genes associated with drug resistance in cancer. , 2015, , .		0
46	Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, 1079-1079.	1.6	0